14.18 亿美元!礼来重金押注基因疗法,可穿透血脑屏障

Insight数据库
07 Apr

近日,Sangamo Therapeutics 宣布,已和礼来达成许可协议,授权礼来利用 Sangamo 新型专有的神经性腺相关病毒(AAV)衣壳 STAC-BBB,该衣壳已在非人类灵长类动物中显示出强大的血脑屏障穿透和神经元转导能力。截图来源:企业官网该协议授予礼来全球独家许可,将 STAC-BBB 衣壳用于一个初始靶点,并有权在支付额外许可靶点费用后增加最多四个额外靶点,以提供静脉注射的基因组...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10